VaramirStart free · no cardSign in
CHRS as of Nov 1 · 08:58 ET
CHRSNasdaqBiological Products, (No Diagnostic Substances)

Coherus Oncology, Inc. · Brief

Next report

4 days

Nov 5 · after closeest.Q3 FY26
Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory
1 of 8≥ implied
avg implied
±24.2%
avg realized
±8.3%
Mar 10 '25±25.7%▲+0.96%×0.04
May 12 '25±14.5%▼−19.11%×1.32
Aug 7 '25±26.7%▼−7.13%×0.27
Q3 FY25±22.2%▼−10.07%×0.45
Jan 13 '26±20.9%▲+3.03%×0.14
Q1 FY26±34.7%▲+1.04%×0.03
May 11 '26±12.4%▼−12.31%×0.99
Q2 FY26±36.1%▼−12.76%×0.35
quarterimplied−40%0+40%realized×
Q2 FY26±36.1%▼−12.76%×0.35
May '26±12.4%▼−12.31%×0.99
Q1 FY26±34.7%▲+1.04%×0.03
Jan '26±20.9%▲+3.03%×0.14
Q3 FY25±22.2%▼−10.07%×0.45
Aug '25±26.7%▼−7.13%×0.27
2 older reports
May '25±14.5%▼−19.11%×1.32
Mar '25±25.7%▲+0.96%×0.04
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · est.

Bull2 of 3

8disclosed supplier and customer ties in SEC filingsSEC filings
145managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

7 of 8recent reports where the move came in under the options-implied rangeEarnings history
3tracked funds holding CHRSN-PORT · Aug 31 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

CHRS report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 23impliedImplied move: ±41.7% into Nov 5 earnings (Oct 23 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.